Global Retirement Partners LLC lowered its position in TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) by 16.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,524 shares of the company's stock after selling 300 shares during the period. Global Retirement Partners LLC's holdings in TransMedics Group were worth $48,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Swiss National Bank lifted its position in TransMedics Group by 7.7% in the first quarter. Swiss National Bank now owns 59,100 shares of the company's stock valued at $1,592,000 after purchasing an additional 4,200 shares during the period. Divisadero Street Capital Management LP purchased a new position in TransMedics Group in the first quarter valued at about $323,000. Signature Wealth Management Partners LLC purchased a new position in TransMedics Group in the first quarter valued at about $329,000. Oppenheimer & Co. Inc. purchased a new position in TransMedics Group in the first quarter valued at about $257,000. Finally, Moody Aldrich Partners LLC increased its holdings in TransMedics Group by 13.4% in the first quarter. Moody Aldrich Partners LLC now owns 188,321 shares of the company's stock valued at $5,073,000 after buying an additional 22,243 shares in the last quarter. Institutional investors and hedge funds own 81.46% of the company's stock.

TransMedics Group Stock Up 6.1 %

TMDX stock opened at $42.52 on Thursday. The stock has a market capitalization of $1.19 billion, a P/E ratio of -24.72 and a beta of 1.48. The company has a debt-to-equity ratio of 0.70, a quick ratio of 3.41 and a current ratio of 4.18. TransMedics Group, Inc. has a one year low of $10.00 and a one year high of $56.41. The company has a 50 day moving average price of $46.36 and a two-hundred day moving average price of $33.78.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TMDX shares. Oppenheimer increased their target price on shares of TransMedics Group from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, August 2nd. Morgan Stanley increased their target price on shares of TransMedics Group from $34.00 to $37.00 and gave the company an "equal weight" rating in a report on Wednesday, August 3rd. Cowen raised their price objective on shares of TransMedics Group from $39.00 to $45.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 26th. JPMorgan Chase & Co. raised shares of TransMedics Group from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $26.00 to $48.00 in a research note on Tuesday, August 2nd. Finally, Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $46.00 to $58.00 in a research note on Thursday, August 4th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $46.00.

Insider Buying and Selling at TransMedics Group

In related news, Director James R. Tobin sold 48,515 shares of the business's stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $35.00, for a total transaction of $1,698,025.00. Following the completion of the sale, the director now owns 302,106 shares of the company's stock, valued at approximately $10,573,710. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 16,409 shares of the business's stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $50.04, for a total transaction of $821,106.36. Following the completion of the transaction, the chief executive officer now directly owns 469,876 shares of the company's stock, valued at approximately $23,512,595.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James R. Tobin sold 48,515 shares of the business's stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $35.00, for a total transaction of $1,698,025.00. Following the transaction, the director now directly owns 302,106 shares of the company's stock, valued at $10,573,710. The disclosure for this sale can be found here. Insiders have sold a total of 177,629 shares of company stock worth $7,036,453 in the last quarter. 8.70% of the stock is owned by insiders.

TransMedics Group Profile

(Get Rating)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Further Reading

• Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
• This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
• A Trio of Q3 Winners With Room to Run
• Can HCA Healthcare Weather the Normalization?
• Can United Natural Foods Fight Both Inflation and the Fed?
• Mullen Automotive Is Ready To Get In Gear

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.